Humans have more than 24,000 distinct HLA-I (HLA-A, -B, and -C) and HLA-II (HLA-DR, HLA-DQ, and HLA-DP) alleles, and their admixture results in polymorphism diversity.248–251 The HLA alleles of the patient determine their tumor-specific neoantigen repertoire that will be presented for T cell recognition. This evidence concerns the gene HLA-A and neoplasm.